Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | LATS1 | O95835 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694698 | 1.00 | PRMT3 (0.49) | PRMT3NQO2LATS1CYP3A4TRPV1 | |
| SCHEMBL22504317 | 0.81 | TRPV1 (0.43) | PRMT3CYP3A4TRPV1HDAC3HDAC1 | |
| SCHEMBL23291125 | 0.80 | PRMT3 (0.60) | PRMT3TRPV1NAMPTHDAC3HDAC1 | |
| SCHEMBL2024124 | 0.80 | CYP17A1 (0.53) | NQO2LATS1CYP3A4NAMPTCA1 | |
| SCHEMBL30627587 | 0.80 | NQO2 (0.47) | PRMT3NQO2LATS1CYP3A4TRPV1 | |
| SCHEMBL30627557 | 0.80 | NQO2 (0.47) | PRMT3NQO2LATS1CYP3A4TRPV1 | |
| SCHEMBL13900839 | 0.80 | NAMPT (0.53) | NQO2CYP3A4NAMPTCA1CA2 | |
| SCHEMBL25176751 | 0.79 | NQO2 (0.47) | NQO2NAMPTCA1CA2CES2 | |
| SCHEMBL30369597 | 0.79 | NQO2 (0.47) | NQO2NAMPTCA1CA2CES2 | |
| SCHEMBL23291128 | 0.78 | CYP17A1 (0.59) | LATS1CYP3A4NAMPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-111164084-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-09-23 | — | — | US | disclosed |
| CN-111164084-A | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2020-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | PRMT3 2249/4885NQO2 2636/4885LATS1 3836/4885 |
| US-20210292334-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | PRMT3 2249/4885NQO2 2636/4885LATS1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.